Journal: EBioMedicine

Article Title: Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.

doi: 10.1016/j.ebiom.2022.104420

Figure Lengend Snippet: Fig. 5: Anti-PD1/chidamide shows an immune response with epigenetic regulation. a, Western blot of Ifn-γ, Cxcl9, Cxcr3, Acetylated histone H3, histone H3, Pd-l1, and β-actin in anti-PD1/chidamide and each monotherapy. b, Western blot of Ifn-γ, Cxcl9, Cxcr3, Acetylated histone H3,

Article Snippet: Tissue homogenates were detected in the Cxcl9 ELISA kit (CSB-EL006252MO, Cusabio) and Ifn-γ ELISA kit (KE10001, Proteintech).

Techniques: Western Blot

Journal: Journal of advanced research

Article Title: Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.

doi: 10.1016/j.jare.2021.03.012

Figure Lengend Snippet: Fig. 2. Nano-HO improved the spatial learning and memory functions of TgCRND8 mice. The spatial learning and memory functions were evaluated using MWMT (n = 9). (A) Experimental design and treatment schedule to evaluate the neuroprotective effects of HO and Nano-HO on TgCRND8 transgenic mice; (B) The latency to find a hidden platform during 4 consecutive days of training; (C) Time spent in the target quadrant; (D) Number of target crossings; (E) Representative swimming tracks of mice in the probe test. Nano-HO decreased the levels of cytokines including TNF-a (F), IL-1b (G) and IL-6 (H), enhanced the level of CCR2 (I) in the brain tissues of TgCRND8 mice (n = 6). Data were expressed as mean ± SEM. # p < 0.05 and ## p < 0.01 when compared with the WT group; * p < 0.05 and ** p < 0.01 when compared with the Tg + vehicle group; ▲ p < 0.05 when compared with free HO group.

Article Snippet: The levels of TNF-a (Catalog no.: ab100747, Abcam, Cambridge, UK), IL-6 (Catalog no.: ab100712, Abcam, Cambridge, UK), IL-1b (Catalog no.: ab100704, Abcam, Cambridge, UK) and CCR2 (Catalog no.: CSB-EL004841MO, CUSABIO, Houston, USA) in the supernatants were determined using commercially available ELISA kits according to the manufacturer’s instructions.

Techniques: Transgenic Assay

Journal: Frontiers in Immunology

Article Title: CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway

doi: 10.3389/fimmu.2025.1658679

Figure Lengend Snippet: CRTC1 in LLC cells suppresses T-cell proliferation and cytotoxicity. (A) Western blot analysis of CRTC1 expression in LLC cells transfected with plasmid overexpressing (oe-CRTC1) or its negative control (oe-NC) and co-cultured with activated CTLL-2 cells at a 1:10 ratio for 24 h (B) CCK-8 assay measuring viability of LLC cells. (C) Flow cytometry analysis of apoptosis in LLC cells. (D) CCK-8 assay assessing T-cell viability. (E-F) Flow cytometry analysis of apoptosis in T cells. (G) Western blot analysis of PD-L1, CXCL10, and CXCL11 expression in co-cultures. (H) ELISA detecting CXCL10 and CXCL11 secretion in supernatants. (I) ELISA measuring IFN-γ and IL-2 levels in supernatants. (J) LDH release assay evaluating T-cell cytotoxicity via supernatant LDH concentration. n = 3. The p-values in panels (A–J) were calculated using ANOVA with Tukey’s post hoc test. *p < 0.05 vs. Control. #p < 0.05 vs. T cells + oe-NC.

Article Snippet: CXCL10 (CSB-E08183m), CXCL11 (CSB-EL006241MO), IFN-γ (CSB-E04578m), and IL-2 (CSB-E04627m) levels in cell supernatants and serum were measured using commercial kits (CUSABIO, Wuhan, China) according to the manufacturer’s instructions.

Techniques: Western Blot, Expressing, Transfection, Plasmid Preparation, Negative Control, Cell Culture, CCK-8 Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Lactate Dehydrogenase Assay, Concentration Assay, Control

Journal: Frontiers in Immunology

Article Title: CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway

doi: 10.3389/fimmu.2025.1658679

Figure Lengend Snippet: CRTC1 in LLC cells inhibits T-cell proliferation and cytotoxicity via Notch1/Akt. (A) Western blot analysis of CRTC1, Notch1, and p-Akt expression in LLC cells transfected with plasmids knocking down CRTC1 (si-CRTC1) and overexpressing Notch1 (oe-Notch1) or their negative controls (si-NC or oe-NC), followed by co-culture with activated CTLL-2 cells (1:10 ratio, 24 h). (B) CCK-8 assay assessing LLC cell viability. (C-D) Flow cytometry analysis of apoptosis in LLC cells. (E) CCK-8 assay measuring T-cell viability. (F) Flow cytometry analysis of apoptosis in T cells. (G) Western blot analysis of PD-L1, CXCL10, and CXCL11 expression in co-cultures. (H) ELISA detecting CXCL10 and CXCL11 secretion in supernatants. (I) ELISA measuring IFN-γ and IL-2 levels in supernatants. (J) LDH release assay evaluating T-cell cytotoxicity. n = 3. The p-values in panels A-K were calculated using ANOVA with Tukey’s post hoc test. *p < 0.05 vs. Control. #p < 0.05 vs. T cells + si-NC. &p < 0.05 vs. T cells + si-CRTC1 + oe-NC.

Article Snippet: CXCL10 (CSB-E08183m), CXCL11 (CSB-EL006241MO), IFN-γ (CSB-E04578m), and IL-2 (CSB-E04627m) levels in cell supernatants and serum were measured using commercial kits (CUSABIO, Wuhan, China) according to the manufacturer’s instructions.

Techniques: Western Blot, Expressing, Transfection, Co-Culture Assay, CCK-8 Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Lactate Dehydrogenase Assay, Control

Journal: Frontiers in Immunology

Article Title: CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway

doi: 10.3389/fimmu.2025.1658679

Figure Lengend Snippet: CRTC1 knockdown synergizes with PD-L1 blockade to suppress tumor growth in vivo . (A) Western blot analysis of CRTC1, Notch1, and p-Akt expression in Lewis xenograft tumors from C57BL/6J mice treated with Atezolizumab combined with plasmids knocking down CRTC1 (si-CRTC1) and overexpressing Notch1 (oe-Notch1) or their negative controls (si-NC or oe-NC). (B) Tumor size in mice bearing Lewis xenografts treated with Atezolizumab, CRTC1 knockdown, and Notch1 overexpression. (C) Tumor volume and weight of Lewis xenografts under combined treatment. (D) Representative H&E staining images of Lewis xenografts post-treatment. Scale bar = 100 μm (top) and 25 μm (bottom). (E) IHC analysis of PD-L1 expression in Lewis xenograft tumors. Scale bar = 100 μm (top) and 25 μm (bottom). (F) Western blot analysis of CXCL10 and CXCL11 expression in tumors. (G) Flow cytometry analysis of CD3+ T-cell infiltration in tumors. (H) ELISA measuring serum IFN-γ and IL-2 levels. n = 5. The p-values in panels (A, C, E–H) were calculated using ANOVA with Tukey’s post hoc test. *p < 0.05 vs. Model. #p < 0.05 vs. Atezolizumab + si-NC. &p < 0.05 vs. Atezolizumab + si-CRTC1 + oe-NC.

Article Snippet: CXCL10 (CSB-E08183m), CXCL11 (CSB-EL006241MO), IFN-γ (CSB-E04578m), and IL-2 (CSB-E04627m) levels in cell supernatants and serum were measured using commercial kits (CUSABIO, Wuhan, China) according to the manufacturer’s instructions.

Techniques: Knockdown, In Vivo, Western Blot, Expressing, Over Expression, Staining, Flow Cytometry, Enzyme-linked Immunosorbent Assay